Literature DB >> 22611565

Successful treatment of epidermolysis bullosa acquisita with rituximab therapy.

Jong Hoon Kim, Sang Eun Lee, Soo-Chan Kim.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22611565     DOI: 10.1111/j.1346-8138.2011.01360.x

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


× No keyword cloud information.
  7 in total

Review 1.  Targeted Therapies for Autoimmune Bullous Diseases: Current Status.

Authors:  Kyle T Amber; Roberto Maglie; Farzan Solimani; Rüdiger Eming; Michael Hertl
Journal:  Drugs       Date:  2018-10       Impact factor: 9.546

2.  [Generalized inflammatory epidermolysis bullosa acquisita initially diagnosed as viral exanthem: a rare disease within the subepidermal blistering disorders].

Authors:  N El-Haj; C Micheli; M Brunner; D Zillikens; C C Zouboulis
Journal:  Hautarzt       Date:  2014-12       Impact factor: 0.751

Review 3.  Systemic diseases and the cornea.

Authors:  Ruchi Shah; Cynthia Amador; Kati Tormanen; Sean Ghiam; Mehrnoosh Saghizadeh; Vaithi Arumugaswami; Ashok Kumar; Andrei A Kramerov; Alexander V Ljubimov
Journal:  Exp Eye Res       Date:  2021-01-21       Impact factor: 3.467

4.  Clinical presentation, pathogenesis, diagnosis, and treatment of epidermolysis bullosa acquisita.

Authors:  Ralf J Ludwig
Journal:  ISRN Dermatol       Date:  2013-07-15

Review 5.  Rituximab therapy in pemphigus and other autoantibody-mediated diseases.

Authors:  Nina A Ran; Aimee S Payne
Journal:  F1000Res       Date:  2017-01-27

Review 6.  Off-Label Uses of Rituximab in Dermatology.

Authors:  Connor Cole; Kyle T Amber
Journal:  Curr Dermatol Rep       Date:  2022-10-06

Review 7.  Epidermolysis Bullosa Acquisita: The 2019 Update.

Authors:  Hiroshi Koga; Catherine Prost-Squarcioni; Hiroaki Iwata; Marcel F Jonkman; Ralf J Ludwig; Katja Bieber
Journal:  Front Med (Lausanne)       Date:  2019-01-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.